EU Post-Market Safety Proposals Stir Concerns About Cost, Complexity
Executive Summary
Even as a proposal to improve the European Union pharmacovigilance system for marketed drugs moves one step closer to adoption, industry is increasingly concerned about its cost and complexity.
You may also be interested in...
OTC Firms Could Gain From Proposed EU Risk Management Plan Revision
AESGP and EFPIA are set to submit a joint proposal to the EMA that would streamline risk management plans for long-marketed products and provide uniform treatment for products approved under differing regulatory procedures.
OTC Firms Could Gain From Proposed EU Risk Management Plan Revision
AESGP and EFPIA are set to submit a joint proposal to the EMA that would streamline risk management plans for long-marketed products and provide uniform treatment for products approved under differing regulatory procedures.
EU Risk Plan Easing For Long-Marketed Products Sought By Industry Groups
EFPIA and AESGP are set to submit a joint proposal to the EMA that would streamline risk management plans for long-marketed products and provide uniform treatment for products approved under differing regulatory procedures.